Improving monoclonal antibody therapies in cancer

Gespeichert in:

Format:	E-Artikel
Sprache:	Englisch

Erschienen:	2000

Schlagwörter:	Trastuzumab Antibody Receptor Herceptin Nature Medicine Palpable Tumour

Anmerkung:	© Adis International Ltd 2000

Übergeordnetes Werk:	Enthalten in: Inpharma weekly - Auckland : ADIS internat., 1975, 1238(2000), 1 vom: Mai, Seite 10-10
Übergeordnetes Werk:	volume:1238 ; year:2000 ; number:1 ; month:05 ; pages:10-10

Links:	Volltext

DOI / URN:	10.2165/00128413-200012380-00020

Katalog-ID:	SPR03630770X

Internformat


LEADER	01000caa a22002652 4500
001	SPR03630770X
003	DE-627
005	20230519071329.0
007	cr uuu---uuuuu
008	201007s2000 xx \|\|\|\|\|o 00\| \|\|eng c
024	7		\|a 10.2165/00128413-200012380-00020 \|2 doi
035			\|a (DE-627)SPR03630770X
035			\|a (SPR)00128413-200012380-00020-e
040			\|a DE-627 \|b ger \|c DE-627 \|e rakwb
041			\|a eng
245	1	0	\|a Improving monoclonal antibody therapies in cancer
264		1	\|c 2000
336			\|a Text \|b txt \|2 rdacontent
337			\|a Computermedien \|b c \|2 rdamedia
338			\|a Online-Ressource \|b cr \|2 rdacarrier
500			\|a © Adis International Ltd 2000
650		4	\|a Trastuzumab \|7 (dpeaa)DE-He213
650		4	\|a Antibody Receptor \|7 (dpeaa)DE-He213
650		4	\|a Herceptin \|7 (dpeaa)DE-He213
650		4	\|a Nature Medicine \|7 (dpeaa)DE-He213
650		4	\|a Palpable Tumour \|7 (dpeaa)DE-He213
773	0	8	\|i Enthalten in \|t Inpharma weekly \|d Auckland : ADIS internat., 1975 \|g 1238(2000), 1 vom: Mai, Seite 10-10 \|w (DE-627)373977859 \|w (DE-600)2127607-9 \|x 2230-6056 \|7 nnns
773	1	8	\|g volume:1238 \|g year:2000 \|g number:1 \|g month:05 \|g pages:10-10
856	4	0	\|u https://dx.doi.org/10.2165/00128413-200012380-00020 \|z lizenzpflichtig \|3 Volltext
912			\|a GBV_USEFLAG_A
912			\|a SYSFLAG_A
912			\|a GBV_SPRINGER
912			\|a SSG-OLC-PHA
912			\|a GBV_ILN_20
951			\|a AR
952			\|d 1238 \|j 2000 \|e 1 \|c 05 \|h 10-10

Indexfelder

matchkey_str	article:22306056:2000----::mrvnmncoaatbdtea
hierarchy_sort_str	2000
publishDate	2000
allfields	10.2165/00128413-200012380-00020 doi (DE-627)SPR03630770X (SPR)00128413-200012380-00020-e DE-627 ger DE-627 rakwb eng Improving monoclonal antibody therapies in cancer 2000 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier © Adis International Ltd 2000 Trastuzumab (dpeaa)DE-He213 Antibody Receptor (dpeaa)DE-He213 Herceptin (dpeaa)DE-He213 Nature Medicine (dpeaa)DE-He213 Palpable Tumour (dpeaa)DE-He213 Enthalten in Inpharma weekly Auckland : ADIS internat., 1975 1238(2000), 1 vom: Mai, Seite 10-10 (DE-627)373977859 (DE-600)2127607-9 2230-6056 nnns volume:1238 year:2000 number:1 month:05 pages:10-10 https://dx.doi.org/10.2165/00128413-200012380-00020 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_20 AR 1238 2000 1 05 10-10
spelling	10.2165/00128413-200012380-00020 doi (DE-627)SPR03630770X (SPR)00128413-200012380-00020-e DE-627 ger DE-627 rakwb eng Improving monoclonal antibody therapies in cancer 2000 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier © Adis International Ltd 2000 Trastuzumab (dpeaa)DE-He213 Antibody Receptor (dpeaa)DE-He213 Herceptin (dpeaa)DE-He213 Nature Medicine (dpeaa)DE-He213 Palpable Tumour (dpeaa)DE-He213 Enthalten in Inpharma weekly Auckland : ADIS internat., 1975 1238(2000), 1 vom: Mai, Seite 10-10 (DE-627)373977859 (DE-600)2127607-9 2230-6056 nnns volume:1238 year:2000 number:1 month:05 pages:10-10 https://dx.doi.org/10.2165/00128413-200012380-00020 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_20 AR 1238 2000 1 05 10-10
allfields_unstemmed	10.2165/00128413-200012380-00020 doi (DE-627)SPR03630770X (SPR)00128413-200012380-00020-e DE-627 ger DE-627 rakwb eng Improving monoclonal antibody therapies in cancer 2000 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier © Adis International Ltd 2000 Trastuzumab (dpeaa)DE-He213 Antibody Receptor (dpeaa)DE-He213 Herceptin (dpeaa)DE-He213 Nature Medicine (dpeaa)DE-He213 Palpable Tumour (dpeaa)DE-He213 Enthalten in Inpharma weekly Auckland : ADIS internat., 1975 1238(2000), 1 vom: Mai, Seite 10-10 (DE-627)373977859 (DE-600)2127607-9 2230-6056 nnns volume:1238 year:2000 number:1 month:05 pages:10-10 https://dx.doi.org/10.2165/00128413-200012380-00020 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_20 AR 1238 2000 1 05 10-10
allfieldsGer	10.2165/00128413-200012380-00020 doi (DE-627)SPR03630770X (SPR)00128413-200012380-00020-e DE-627 ger DE-627 rakwb eng Improving monoclonal antibody therapies in cancer 2000 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier © Adis International Ltd 2000 Trastuzumab (dpeaa)DE-He213 Antibody Receptor (dpeaa)DE-He213 Herceptin (dpeaa)DE-He213 Nature Medicine (dpeaa)DE-He213 Palpable Tumour (dpeaa)DE-He213 Enthalten in Inpharma weekly Auckland : ADIS internat., 1975 1238(2000), 1 vom: Mai, Seite 10-10 (DE-627)373977859 (DE-600)2127607-9 2230-6056 nnns volume:1238 year:2000 number:1 month:05 pages:10-10 https://dx.doi.org/10.2165/00128413-200012380-00020 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_20 AR 1238 2000 1 05 10-10
allfieldsSound	10.2165/00128413-200012380-00020 doi (DE-627)SPR03630770X (SPR)00128413-200012380-00020-e DE-627 ger DE-627 rakwb eng Improving monoclonal antibody therapies in cancer 2000 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier © Adis International Ltd 2000 Trastuzumab (dpeaa)DE-He213 Antibody Receptor (dpeaa)DE-He213 Herceptin (dpeaa)DE-He213 Nature Medicine (dpeaa)DE-He213 Palpable Tumour (dpeaa)DE-He213 Enthalten in Inpharma weekly Auckland : ADIS internat., 1975 1238(2000), 1 vom: Mai, Seite 10-10 (DE-627)373977859 (DE-600)2127607-9 2230-6056 nnns volume:1238 year:2000 number:1 month:05 pages:10-10 https://dx.doi.org/10.2165/00128413-200012380-00020 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_20 AR 1238 2000 1 05 10-10
language	English
source	Enthalten in Inpharma weekly 1238(2000), 1 vom: Mai, Seite 10-10 volume:1238 year:2000 number:1 month:05 pages:10-10
sourceStr	Enthalten in Inpharma weekly 1238(2000), 1 vom: Mai, Seite 10-10 volume:1238 year:2000 number:1 month:05 pages:10-10
format_phy_str_mv	Article
institution	findex.gbv.de
topic_facet	Trastuzumab Antibody Receptor Herceptin Nature Medicine Palpable Tumour
isfreeaccess_bool	false
container_title	Inpharma weekly
publishDateDaySort_date	2000-05-01T00:00:00Z
hierarchy_top_id	373977859
id	SPR03630770X
language_de	englisch
fullrecord	<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">SPR03630770X</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230519071329.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">201007s2000 xx \|\|\|\|\|o 00\| \|\|eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.2165/00128413-200012380-00020</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)SPR03630770X</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(SPR)00128413-200012380-00020-e</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Improving monoclonal antibody therapies in cancer</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2000</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">© Adis International Ltd 2000</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Trastuzumab</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Antibody Receptor</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Herceptin</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Nature Medicine</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Palpable Tumour</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="t">Inpharma weekly</subfield><subfield code="d">Auckland : ADIS internat., 1975</subfield><subfield code="g">1238(2000), 1 vom: Mai, Seite 10-10</subfield><subfield code="w">(DE-627)373977859</subfield><subfield code="w">(DE-600)2127607-9</subfield><subfield code="x">2230-6056</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:1238</subfield><subfield code="g">year:2000</subfield><subfield code="g">number:1</subfield><subfield code="g">month:05</subfield><subfield code="g">pages:10-10</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://dx.doi.org/10.2165/00128413-200012380-00020</subfield><subfield code="z">lizenzpflichtig</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_SPRINGER</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">1238</subfield><subfield code="j">2000</subfield><subfield code="e">1</subfield><subfield code="c">05</subfield><subfield code="h">10-10</subfield></datafield></record></collection>
ppnlink_with_tag_str_mv	@@773@@(DE-627)373977859
format	electronic Article
delete_txt_mv	keep
collection	springer
remote_str	true
illustrated	Not Illustrated
issn	2230-6056
topic_title	Improving monoclonal antibody therapies in cancer Trastuzumab (dpeaa)DE-He213 Antibody Receptor (dpeaa)DE-He213 Herceptin (dpeaa)DE-He213 Nature Medicine (dpeaa)DE-He213 Palpable Tumour (dpeaa)DE-He213
topic	misc Trastuzumab misc Antibody Receptor misc Herceptin misc Nature Medicine misc Palpable Tumour
spellingShingle	misc Trastuzumab misc Antibody Receptor misc Herceptin misc Nature Medicine misc Palpable Tumour Improving monoclonal antibody therapies in cancer
topic_unstemmed	misc Trastuzumab misc Antibody Receptor misc Herceptin misc Nature Medicine misc Palpable Tumour
topic_browse	misc Trastuzumab misc Antibody Receptor misc Herceptin misc Nature Medicine misc Palpable Tumour
format_facet	Elektronische Aufsätze Aufsätze Elektronische Ressource
format_main_str_mv	Text Zeitschrift/Artikel
carriertype_str_mv	cr
hierarchy_parent_title	Inpharma weekly
hierarchy_parent_id	373977859
hierarchy_top_title	Inpharma weekly
isfreeaccess_txt	false
familylinks_str_mv	(DE-627)373977859 (DE-600)2127607-9
title	Improving monoclonal antibody therapies in cancer
ctrlnum	(DE-627)SPR03630770X (SPR)00128413-200012380-00020-e
title_full	Improving monoclonal antibody therapies in cancer
journal	Inpharma weekly
journalStr	Inpharma weekly
lang_code	eng
isOA_bool	false
recordtype	marc
publishDateSort	2000
contenttype_str_mv	txt
container_start_page	10
container_volume	1238
format_se	Elektronische Aufsätze
doi_str_mv	10.2165/00128413-200012380-00020
title_sort	improving monoclonal antibody therapies in cancer
title_auth	Improving monoclonal antibody therapies in cancer
abstract	© Adis International Ltd 2000
abstractGer	© Adis International Ltd 2000
abstract_unstemmed	© Adis International Ltd 2000
collection_details	GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_20
container_issue	1
title_short	Improving monoclonal antibody therapies in cancer
url	https://dx.doi.org/10.2165/00128413-200012380-00020
remote_bool	true
ppnlink	373977859
mediatype_str_mv	c
isOA_txt	false
hochschulschrift_bool	false
doi_str	10.2165/00128413-200012380-00020
up_date	2024-07-03T16:59:18.250Z
_version_	1803577939199000576
fullrecord_marcxml	<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">SPR03630770X</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230519071329.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">201007s2000 xx \|\|\|\|\|o 00\| \|\|eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.2165/00128413-200012380-00020</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)SPR03630770X</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(SPR)00128413-200012380-00020-e</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Improving monoclonal antibody therapies in cancer</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2000</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">© Adis International Ltd 2000</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Trastuzumab</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Antibody Receptor</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Herceptin</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Nature Medicine</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Palpable Tumour</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="t">Inpharma weekly</subfield><subfield code="d">Auckland : ADIS internat., 1975</subfield><subfield code="g">1238(2000), 1 vom: Mai, Seite 10-10</subfield><subfield code="w">(DE-627)373977859</subfield><subfield code="w">(DE-600)2127607-9</subfield><subfield code="x">2230-6056</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:1238</subfield><subfield code="g">year:2000</subfield><subfield code="g">number:1</subfield><subfield code="g">month:05</subfield><subfield code="g">pages:10-10</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://dx.doi.org/10.2165/00128413-200012380-00020</subfield><subfield code="z">lizenzpflichtig</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_SPRINGER</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">1238</subfield><subfield code="j">2000</subfield><subfield code="e">1</subfield><subfield code="c">05</subfield><subfield code="h">10-10</subfield></datafield></record></collection>
score	7.398551

Nicht das Richtige dabei?

Schreiben Sie uns!

Improving monoclonal antibody therapies in cancer

Nicht das Richtige dabei?

Zugang & Verfügbarkeit

Vorhandene Bände

Nicht das Richtige dabei?